Pacira price target lowered to $55 from $60 at Truist

Truist analyst Greg Fraser lowered the firm’s price target on Pacira to $55 from $60 and keeps a Buy rating on the shares. The 340B discounting despite the 4% volume growth has prompted the management to trim guidance, the analyst tells investors in a research note. Truist adds that margins are unlikely to improve until the full effects of new 200L facility, closure of 25L or 45L facility and improvements at Swindon are evident.